Osteoarthritis, is a degenerative disease of the joints, involving degeneration of the joints, including cartilage bone and ligaments. Symptoms may include joint pain, tenderness, and stiffness swelling due to fluid retention. Once the cartilage is worn out the bones begin to get damaged. This leads to decreased movement, pain and damage of the soft tissues around the joints.
Stem cell therapy has been demonstrated to induce profound healing of joints in various forms of arthritis. Besides healing of damaged tissues, stem cells have the unique ability to modulate the immune system so as to shut off pathological causes of arthritis, while regenerating the diseased tissues..
The stem cells used in these therapies are called allogeneic mesenchymal stem cells. These cells are harvested from donated human umbilical cords tissue from normal, healthy births. These mesenchymal stem cells are tested for any bacterial or viral infections before being cleared for therapeutic purposes. These cells go through very stringent screening process to find cells that have the best anti-inflammatory activity, the best immune modulating capacity, and the best ability to stimulate regeneration. We also use Bone Marrow derived mesenchymal stem cell along with allogenic stem cells.
Advantages of treating with allogenic human umbilical cord tissue derived mesenchymal stem cells.
- Since HUCT mesenchymal stem cells have little immunogenic foot print, cell rejection is not an issue and Human Leukocyte Antigen (HLA) typing is not necessary.
- The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened, selected and amplified.
- As these cells can be expanded they can be administered multiple times over the course of days in uniform dosages that contain high cell counts.
- Umbilical cord tissue provides an abundant supply of mesenchymal stem cells.
- There is a growing body of evidence showing that mesenchymal stem cells from umbilical cords are more young and robust than mesenchymal stem cells from other sources such as fat or bone marrow.
Human umbilical cord tissue-derived mesenchymal stem cells (MSCs) are currently being used in the United States.
These cells serve as the starting material for cellular products used in MSC clinical trials for two Duchenne’s muscular dystrophy patients under US FDA’s designation of
The stem cells are administered by a qualified physician into the affected joints (intra-articular injection) and intravenously (IV). Extra intra-articular injections are done for multiple joints as medical requirements dictate.
A typical treatment protocol takes about 4 days
- Medical evaluation and blood testing
- 1 – 2 Intra-articular (into the joint) injections of HUCT mesenchymal stem cells and bone marrow derived mesenchymal stem cells as needed
- 5 Intravenous injections (IV) of HUCT mesenchymal stem cells
We will monitor your post-treatment progress on a regular basis.
Regular follow-up also helps us evaluate the effectiveness of our treatments and improve our protocols.
Therefore, our medical staff will be contacting you after 1 month, 3 months, 4 months, and 1 year after the treatment to follow up on your condition.